

Association of Breast Surgery
Advanced Skills in Breast Disease Management Course
22nd to 24th September 2021, Selwyn College Cambridge

Provisional Programme

Day 1: Screening, Diagnosis and Benign Breast Conditions

09:15 to 09:25	Registration and refreshments	
09:25 to 09:30	Welcome & introduction	Faculty TBC
09:30 to 09:45	Opening remarks	
Plenary International Speaker		
09:45 to 10:15	Principles of Screening	
10:15 to 10:45	Symptomatic (triple) assessment	
Learning outcomes: Sensitivities of modalities and medico-legal aspects		
10:45 to 11:15	Breast Screening	
Learning outcomes: Principles (including screening trials), QA processes, duty of candour and B3 lesions		
11:15 to 11:45	Tea & coffee break	
11:45 to 12:30	Breast pathology	
Learning outcomes: Principles, histopathology and grading of cancers, immunohistochemistry (and FISH), genomics		
12:30 to 13:00	Breast imaging update	
Learning outcomes: Digital breast tomosynthesis, MRI, contrast enhanced MMG, staging investigations (CT/PET/bone scans)		
13:00 to 14:00	Lunch	
14:00 to 14:30	Breast pain	
Learning outcomes: Incidence, assessment (opportunistic MMG), management and complex cases		
14:30 to 15:00	Nipple discharge	
Learning outcomes: Assessment, diagnostic features of 'pathological' nipple discharge and management		
15:00 to 15:30	Breast sepsis	
Learning outcomes: Assessment of mastitis, peri-areolar sepsis, breast abscess and mammary fistula, smoking habits, management		
15:30 to 16:00	Gynaecomastia	

Learning outcomes: Assessment, diagnostic workup (including blood tests) and management		
16:00 to 16:30	Tea & coffee break	
16:30 to 17:00	Psychological Care	
17:00 to 18:00	Diagnostic and screening MDT	
Learning outcomes: Implants, discharge, sepsis and pregnancy, duty of candour		

Day 2: Breast Cancer: Cancer Biology, Surgery and Risk

08:00 to 08:30	Refreshments	
08:30 to 09:15	Breast cancer tumour biology	
Learning outcomes: Molecular subtypes, carcinogenesis, integration of '-omics' with histopathology and impact of genetic information on treatment decisions		
09:15 to 10:00	Risk: Lifestyle and modifiable risk factors	
Learning outcomes: Exogenous hormones, obesity and weight gain, alcohol intake, exercise, smoking and breast reconstruction outcomes		
10:00 to 10:30	Familial and genetic risk assessment	
Learning outcomes: Risk assessment based on family history (1 st , 2 nd , 3 rd degree relatives, age at diagnosis), threshold risk levels for genetic testing and/or referral to clinical genetics, management of risk (surgery versus surveillance)		
10:30 to 11:00	Tea and coffee break	
11:00 to 11:30	Risk reducing surgery	
Learning outcomes: Indications, pathways and timing of bilateral mastectomy or oophorectomy, clinical outcomes		
11:30 to 12:00	DCIS	
Learning outcomes: Risk factors for recurrent DCIS, adjuvant treatments (RT and/or hormones), active monitoring of low risk cases		
12:00 to 12:45	Local recurrence after breast conserving surgery	
Learning outcomes: Surgical margins and consensus statements on definition of negative margin, intra-operative margin assessment (FS, TIMC and newer technologies)		
12:45 to 13:45	Lunch	
13:45 to 14:15	Breast conservation: oncological considerations and oncoplastic techniques	
Learning outcomes: Placement of incisions, use of surgical clips, newer 3-D marker clips, topography of surgical cavity and radiotherapy boost, volume displacement and replacement techniques		
14:15 to 14:45	Mastectomy: oncological considerations, skin and nipple sparing mastectomy	

Learning outcomes: Surgical planning, oncoplastic plane, SSM/modified SSM, indications and incisions for therapeutic NSM		
14:45 to 15:15	The contralateral breast in unilateral breast cancer	
Learning outcomes: Incidence of contralateral breast cancer, evidence for impact on survival outcomes, preference-sensitive decision-making and protocols		
15:15 to 15:45	Tea and coffee break	
15:45 to 16:15	Management of the axilla	
Learning outcomes: Role of axillary dissection in modern era, SLN biopsy and management of SLN positive patients, axillary RT, omission of surgical staging of axilla		
16:15 to 16:45	Surgical considerations of neoadjuvant therapy	
Learning outcomes: Stratification and patient selection (tumour size and biological subtype), predictors of pCR, loco-regional treatment of breast/axilla in exceptional responders with HER2 positive and TNBC		
16:45 to 18:00	Pre-operative surgical MDT	
Learning outcomes: Multifocality, nipple-areola complex, micrometastases, localization methods, breast conservation versus mastectomy and standard or oncoplastic breast conserving procedure. SSM, NSM and types of immediate whole breast reconstruction		

Day 3: Adjuvant and Systemic Treatment

08:00 to 08:30	Refreshments	
08:30 to 09:00	Advances in radiotherapy for breast cancer patients	
Learning outcomes: Indications for post-mastectomy and regional nodal radiotherapy, intensity modulated radiotherapy and brachytherapy (intraoperative or multiple catheter techniques), dual boost for multiple ipsilateral cancers, omission of radiotherapy in good prognosis patients (PRIMETIME trial)		
09:00 to 09:30	Radiotherapy, breast reconstruction and implants	
Learning outcomes: Outcomes and level of evidence (MROC data) timing of reconstruction and whether to irradiate expander or permanent implant, delayed-immediate and delayed breast reconstruction, complications and delays in starting adjuvant treatments		
09:30 to 10:00	Adjuvant chemotherapy and biological therapies	
Learning outcomes: Regimens, management of complications (neutropenic sepsis), newer targeted therapies and compound toxicities		
10:00 to 10:30	Adjuvant endocrine therapy: pre and post-menopausal patients	

Learning outcomes: Tamoxifen, aromatase inhibitor or sequential therapy, extended hormonal therapy, LHRH analogues, combinatorial therapies with endocrine agents and CDK4/6 inhibitors, compliance issues		
10:30 to 11:00	Tea & coffee break	
11:00 to 11:30	Bone protection and bisphosphonates	
Learning outcomes: Bone protection during AI therapy, survival data		
11:30 to 12:00	Neoadjuvant chemotherapy	
Learning outcomes: Indications for neoadjuvant chemotherapy based on tumour size and biology (equivalence of survival from NSABP B-18 trial), dual anti-HER2 therapies, predictors of pCR, I-SPY platform trial, local recurrence after breast conserving surgery		
12:00 to 13:00	Lunch	
13:00 to 13:20	Risk assessment tools in the MDT	
Learning outcomes: Computer-based risk assessment tools, PREDICT (updated version to incorporate HER2 and Ki-67 status)		
13:20 to 13:40	Risk assessment tools: breast and axilla	
Learning outcomes: Risk assessment tools: Breast and axilla To include MSK nomograms: DCIS and for axilla		
13:40 to 14:10	Pregnancy and fertility	
Learning outcomes: Pregnancy and breast cancer specific survival, treatment of pregnancy-associated breast cancer, management of fertility during breast cancer treatment (LHRH analogues, egg storage)		
14:10 to 14:30	San Antonio update	
Learning outcomes: Key papers, surgical advances and potentially practice changing clinical data		
14:30 to 14:45	Tea & coffee break	
14:45 to 16:00	Postoperative adjuvant therapy MDT	
Learning outcomes: Efficacy, tolerability, compliance and cost of adjuvant treatments (radiotherapy and systemic treatments [chemotherapy, hormonal therapy, biological therapy and bisphosphonates])		
16:00 to 16:30	Feedback and close of meeting	